Term
| myelosuppression, nausea/vomiting, alopecia, menstrual irregularities |
|
Definition
|
|
Term
| nausea/vomiting, bone marrow suppression, hemorrhagic cystitis (bladder irritation) |
|
Definition
|
|
Term
| nausea/vomiting, delayed hematopoietic depression, CNS toxicity, pulmonary fibrosis (with chronic use) |
|
Definition
|
|
Term
| nephrotoxic (administer with vigorous hydration and mannitol!), severe n/v (administer 5-HT3 antagonists) |
|
Definition
|
|
Term
| less nephrotoxicity but more myelotoxic |
|
Definition
|
|
Term
| myelosuppressive: producing severe leukopenia, bone marrow aplasia, and thrombocytopenia; GI toxicity (oral dose); hepatic dysfunction (prolonged low-doses); renal toxicity |
|
Definition
|
|
Term
| Myelosuppression (leukopenia), NV, and oral/GI ulceration |
|
Definition
|
|
Term
| high doses can damage the liver, heart, and other organs |
|
Definition
|
|
Term
| well tolerated, myelosuppression is generally mild. long term use may cause hepatotoxicity (jaundice); hyperuricemia and hyperuricosuria. |
|
Definition
|
|
Term
| Myelosuppression but less hepatotoxicity compared to 6-MP |
|
Definition
|
|
Term
| main dose-limiting toxicity is myelosuppression and immunosuppression. patients are at risk for opportunistic infections |
|
Definition
|
|
Term
| can cause acute and chronic cardiomyopathy (patient will have arrhythmia or delayed Cardiotoxicity = CHF. Dose dependent!); can also cause local tissue necrosis, myelosuppression |
|
Definition
| Doxorubicin, daunorubicn and to a less extent mitoxantrone |
|
|
Term
| bone marrow suppression (64%), mucocutaneous toxicity (4%) phlebitis, puritis, and stomatisis; pulmonary toxicity (rare but potneitally serious and fatal); Hemolytic-uremic syndrome; extravasation |
|
Definition
|
|
Term
| age related, cumulative dose-related pulmonary toxicity |
|
Definition
|
|
Term
| hypersensitivity reaction (90%) w/ 1st or 2nd dose; neuropathy, alopecia, necrosis with extravasation |
|
Definition
|
|
Term
| severe myelosuppression, diarrhea, severe vomiting (not used clinically because of severe SEs) |
|
Definition
|
|
Term
| myelosuppression, diarrhea |
|
Definition
|
|
Term
| myelosuppression (UGT1A1 gene carriers (10%) at increased risk for severe/life threatening neutropenia); Diarrhea (25%)- early during infusion- cholinergic effect, treat with atropine, late (>24 hrs, severe) use immodium |
|
Definition
|
|
Term
|
Definition
| Epipodopyllotoxins (Etoposide (VP-16) |
|
|
